Sasha Still1, Molly Szerlip2, Michael Mack3. 1. Department of General Surgery, Baylor University Medical Center, Dallas, TX, USA. 2. Department of Cardiology, The Heart Hospital Baylor Plano, 4716 Alliance Blvd Pavilion 2 Suite 300, Plano, TX, 75093, USA. Molly.Szerlip@BSWHealth.org. 3. Department of Cardiothoracic Surgery, The Heart Hospital Baylor Plano, Plano, TX, USA.
Abstract
PURPOSE OF REVIEW: To determine what influences patients and physicians to choose between transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) in intermediate-surgical-risk patients with severe, symptomatic aortic stenosis. RECENT FINDINGS: Advances in transcatheter valve technology, techniques, and trials demonstrating non-inferiority compared to surgical aortic valve replacement (SAVR) have led to expanded eligibility of transcatheter aortic valve replacement (TAVR) to both intermediate-risk patients in clinical practice and low-risk patients in pivotal trials. Since lower-risk individuals tend to be younger and good operative candidates, concerns of valve durability, procedure-related morbidity, and patient survivability require careful consideration. Results from the PARTNER II intermediate risk trials and SURTAVI trials have given us insight into the benefits and potential risks of both treatment modalities. In this article, we review the brief yet remarkable history of TAVR and discuss its role in the treatment of intermediate-surgical-risk patients.
PURPOSE OF REVIEW: To determine what influences patients and physicians to choose between transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) in intermediate-surgical-risk patients with severe, symptomatic aortic stenosis. RECENT FINDINGS: Advances in transcatheter valve technology, techniques, and trials demonstrating non-inferiority compared to surgical aortic valve replacement (SAVR) have led to expanded eligibility of transcatheter aortic valve replacement (TAVR) to both intermediate-risk patients in clinical practice and low-risk patients in pivotal trials. Since lower-risk individuals tend to be younger and good operative candidates, concerns of valve durability, procedure-related morbidity, and patient survivability require careful consideration. Results from the PARTNER II intermediate risk trials and SURTAVI trials have given us insight into the benefits and potential risks of both treatment modalities. In this article, we review the brief yet remarkable history of TAVR and discuss its role in the treatment of intermediate-surgical-risk patients.
Authors: Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock Journal: N Engl J Med Date: 2011-06-05 Impact factor: 91.245
Authors: Alain Cribier; Helene Eltchaninoff; Assaf Bash; Nicolas Borenstein; Christophe Tron; Fabrice Bauer; Genevieve Derumeaux; Frederic Anselme; François Laborde; Martin B Leon Journal: Circulation Date: 2002-12-10 Impact factor: 29.690
Authors: Josep Rodés-Cabau; Jean-Bernard Masson; Robert C Welsh; Bruno Garcia Del Blanco; Marc Pelletier; John G Webb; Faisal Al-Qoofi; Philippe Généreux; Gabriel Maluenda; Martin Thoenes; Jean-Michel Paradis; Chekrallah Chamandi; Vicenç Serra; Eric Dumont; Mélanie Côté Journal: JACC Cardiovasc Interv Date: 2017-05-17 Impact factor: 11.195
Authors: Alexander Ghanem; Andreas Müller; Claas P Nähle; Justine Kocurek; Nikos Werner; Christoph Hammerstingl; Hans H Schild; Jörg O Schwab; Fritz Mellert; Rolf Fimmers; Georg Nickenig; Daniel Thomas Journal: J Am Coll Cardiol Date: 2010-02-24 Impact factor: 24.094
Authors: Philipp Kahlert; Stephan C Knipp; Marc Schlamann; Matthias Thielmann; Fadi Al-Rashid; Marcel Weber; Uwe Johansson; Daniel Wendt; Heinz G Jakob; Michael Forsting; Stefan Sack; Raimund Erbel; Holger Eggebrecht Journal: Circulation Date: 2010-02-23 Impact factor: 29.690
Authors: George C M Siontis; Peter Jüni; Thomas Pilgrim; Stefan Stortecky; Lutz Büllesfeld; Bernhard Meier; Peter Wenaweser; Stephan Windecker Journal: J Am Coll Cardiol Date: 2014-07-15 Impact factor: 24.094
Authors: Danny Dvir; John G Webb; Sabine Bleiziffer; Miralem Pasic; Ron Waksman; Susheel Kodali; Marco Barbanti; Azeem Latib; Ulrich Schaefer; Josep Rodés-Cabau; Hendrik Treede; Nicolo Piazza; David Hildick-Smith; Dominique Himbert; Thomas Walther; Christian Hengstenberg; Henrik Nissen; Raffi Bekeredjian; Patrizia Presbitero; Enrico Ferrari; Amit Segev; Arend de Weger; Stephan Windecker; Neil E Moat; Massimo Napodano; Manuel Wilbring; Alfredo G Cerillo; Stephen Brecker; Didier Tchetche; Thierry Lefèvre; Federico De Marco; Claudia Fiorina; Anna Sonia Petronio; Rui C Teles; Luca Testa; Jean-Claude Laborde; Martin B Leon; Ran Kornowski Journal: JAMA Date: 2014-07 Impact factor: 56.272